UK psychedelic medicine specialist Beckley Psytech has raised an impressive £58 million (around $80 million) in an oversubscribed second-round financing that will help fund clinical development of its ...
Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinical development of ...
ATAI Life Sciences ( (ATAI)) has issued an update. On November 4, 2025, ATAI Life Sciences held an extraordinary general meeting to discuss the acquisition of Beckley Psytech Limited and the company’s ...
An update from ATAI Life Sciences ( (ATAI)) is now available. On November 5, 2025, Atai Beckley N.V. completed its acquisition of Beckley Psytech Limited, resulting in a strategic combination to form ...
NEW YORK and AMSTERDAM, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) ("AtaiBeckley” or "Company”), a clinical-stage biopharmaceutical company on a mission to transform patient ...
Breakthrough Therapy designation recognizes the potential of BPL-003 to deliver substantial improvement over existing therapies for patients with treatment-resistant depression FDA designation follows ...
ATAI Life Sciences N.V. (NASDAQ:ATAI) filed an update Friday regarding its planned acquisition of Beckley Psytech Limited, a company based in England and Wales. The update, disclosed in a press ...
NEW YORK and AMSTERDAM and OXFORD, United Kingdom, Sept. 23, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai"), a clinical-stage biopharmaceutical company on a mission to develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback